WHAT IS CBDV
CBDV (cannabidivarin) is a non-psychoactive cannabinoid structurally similar to CBD but with a shorter propyl (3-carbon) side chain instead of CBD’s pentyl (5-carbon) side chain. The 2-carbon difference subtly changes receptor interactions and pharmacokinetic profile.
CBDV occurs in cannabis at low concentrations (typically 0.1-1%). Some specialty African landrace cultivars produce higher CBDV (up to 5%). Commercial CBDV products are typically extracted from these high-CBDV cultivars or synthesized for research and product applications.
Like CBD, CBDV is non-psychoactive and acts through non-CB1 pathways including TRPV1 and other ion channels. Research interest centers on epilepsy and autism spectrum applications.
RESEARCH FOCUS
Epilepsy: CBDV has shown anticonvulsant activity in preclinical models. GW Pharmaceuticals (the company behind FDA-approved CBD-based Epidiolex) developed GWP42006 — a CBDV-based investigational drug — but Phase II clinical trials in 2018 didn’t meet primary endpoints. Research continues with refined dosing and patient populations.
Autism spectrum disorder: Preliminary research suggests CBDV may modulate behavioral symptoms associated with autism. Multiple ongoing clinical trials are evaluating CBDV in autism populations.
Rett syndrome: A rare neurological disorder being studied for CBDV intervention.
Clinical translation is still early. CBDV is not a substitute for CBD in established applications (anxiety, sleep, inflammation) — those use cases have stronger CBD evidence. CBDV is a research-frontier cannabinoid with specific niches.
